Cargando…
Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598345/ https://www.ncbi.nlm.nih.gov/pubmed/34826735 http://dx.doi.org/10.1016/j.jneuroim.2021.577780 |
| _version_ | 1784600805457788928 |
|---|---|
| author | Caravagna, Céline |
| author_facet | Caravagna, Céline |
| author_sort | Caravagna, Céline |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8598345 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85983452021-11-18 Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol Caravagna, Céline J Neuroimmunol Letter to the Editor Elsevier B.V. 2022-01-15 2021-11-18 /pmc/articles/PMC8598345/ /pubmed/34826735 http://dx.doi.org/10.1016/j.jneuroim.2021.577780 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Caravagna, Céline Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol |
| title | Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol |
| title_full | Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol |
| title_fullStr | Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol |
| title_full_unstemmed | Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol |
| title_short | Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol |
| title_sort | comments on “initial clinical manifestation of multiple sclerosis after immunization with the pfizer-biontech covid-19 vaccine” by fujimori et al., (2021), j neuroimmunol |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598345/ https://www.ncbi.nlm.nih.gov/pubmed/34826735 http://dx.doi.org/10.1016/j.jneuroim.2021.577780 |
| work_keys_str_mv | AT caravagnaceline commentsoninitialclinicalmanifestationofmultiplesclerosisafterimmunizationwiththepfizerbiontechcovid19vaccinebyfujimorietal2021jneuroimmunol |